AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

ALGORAE PHARMACEUTICALS LTD

0.007

+0.000

Volume:- -

Turnover:- -

Market Cap:11.81M

PE:-8.68

High:0.007

Open:0.007

Low:0.007

Close:0.007

Loading ...

Overview Company News Filings

Algorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening

MT Newswires Live

BRIEF-Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre

Algorae Pharmaceuticals Ltd - Partners With Peter Maccallum Cancer Centre for AI- Driven Drug Synergy Screening

THOMSON REUTERS

Algorae Pharmaceuticals strengthens leadership team with appointment of new chief commercial officer

Algorae Pharmaceuticals advances R&D pipeline as AI-driven drug trials continue

Weekly wrap: record highs followed by a slight slip

BUZZ-Australia's Algorae Pharmaceuticals gains after positive drug assessment

Algorae Pharma’s drug AI-168 shows cardioprotection, outperforms beta blockers in pre-clinical studies of proliferation

Monash tests show strong cardioprotective qualities for Algorae drug candidate

The Market Herald

Algorae Pharmaceuticals strengthens advisory board with appointment of Dr Sarah Siggins

Algorae Pharmaceuticals to study 24 new drug targets generated by AlgoraeOS AI platform

BRIEF-Algorae Pharmaceuticals Says Cessation Of Co's American Depositary Share Deposit Agreement

Algorae Pharmaceuticals - Cessation of Co's American Depositary Share Deposit Agreement, Marking End of Trading of Algorae Securities on Otcqb in US

THOMSON REUTERS

ASX Penny Stocks To Watch In November 2024

Simply Wall St.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/1AI.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"1AI.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","market":"AU","secType":"STK","nameCN":"ALGORAE PHARMACEUTICALS LTD","latestPrice":0.007,"timestamp":1746771120000,"preClose":0.007,"halted":0,"volume":0,"delay":0,"nameEN":"ALGORAE PHARMACEUTICALS LTD","floatShares":1046585658,"shares":1687394731,"eps":-0.000806,"marketStatus":"Market Closed","change":0,"latestTime":"05-09 16:12:00 AEST","open":0.007,"high":0.007,"low":0.007,"amount":0,"amplitude":0,"askPrice":0.007,"askSize":1385105,"bidPrice":0.006,"bidSize":1000000,"shortable":3,"etf":0,"ttmEps":-0.000806,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1747008000000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":0.007,"openAndCloseTimeList":[[1746748800000,1746770400000]],"volumeRatio":0,"lotSize":1,"tradeCurrency":"AUD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"1AI.AU\",,,,,undefined,":{"symbol":"1AI.AU","floatShares":1046585658,"roa":"-14.71%","roe":"-43.16%","lyrEps":-0.00126,"shares":1687394731,"dividePrice":0,"high":0.007,"amplitude":0,"preClose":0.007,"low":0.007,"week52Low":0.005,"pbRate":"4.94","psRate":"94.34","week52High":0.013,"institutionHeld":0,"latestPrice":0.007,"committee":-0.161462,"eps":-0.000806,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.000806,"open":0.007,"prevYearClose":0.006,"prevWeekClose":0.006,"prevMonthClose":0.006,"prevQuarterClose":0.005,"fiveDayClose":0.006,"twentyDayClose":0.005,"sixtyDayClose":0.006},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"1AI.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2533176539","title":"Algorae Pharmaceuticals Working With Victoria Cancer Center for Drug Synergy Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2533176539","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533176539?lang=en_us&edition=fundamental","pubTime":"2025-05-08 10:58","pubTimestamp":1746673130,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals  is working with the Victorian Center for Functional Genomics  at Peter MacCallum Cancer Center to validate artificial intelligence-predicted drug interactions through screening, according to a Thursday filing with the Australian bourse.The study will assess 24 drug candidates using VCFG's advanced screening platform to confirm drug combinations' efficacy across four cancer cell lines, the filing said.The data analysis is expected to be completed within three weeks of each screen run, with the full dataset expected to be completed within six months, per the filing.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["1AI.AU","BK4095","BK7067","VCCTF"],"gpt_icon":0},{"id":"2533134099","title":"BRIEF-Algorae Pharmaceuticals Partners With Peter Maccallum Cancer Centre","url":"https://stock-news.laohu8.com/highlight/detail?id=2533134099","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533134099?lang=en_us&edition=fundamental","pubTime":"2025-05-08 09:24","pubTimestamp":1746667470,"startTime":"0","endTime":"0","summary":"BRIEF-Algorae Pharmaceuticals Partners With Peter Maccallum Cancer CentreMay 8 (Reuters) - Algorae Pharmaceuticals Ltd 1AI.AX:PARTNERS WITH PETER MACCALLUM CANCER CENTRE FOR AI- DRIVEN DRUG SYNERGY SCREENINGFurther company coverage: 1AI.AX ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250508:nFWN3RF37H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2533996312","title":"Algorae Pharmaceuticals Ltd - Partners With Peter Maccallum Cancer Centre for AI- Driven Drug Synergy Screening","url":"https://stock-news.laohu8.com/highlight/detail?id=2533996312","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533996312?lang=en_us&edition=fundamental","pubTime":"2025-05-08 07:01","pubTimestamp":1746658910,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250507:nFWN3RF37H:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["1AI.AU","BK7067"],"gpt_icon":0},{"id":"2524405826","title":"Algorae Pharmaceuticals strengthens leadership team with appointment of new chief commercial officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2524405826","media":"Small Caps","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524405826?lang=en_us&edition=fundamental","pubTime":"2025-04-03 12:49","pubTimestamp":1743655758,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals  has strengthened its leadership team with the appointment of seasoned pharmaceutical executive Vishal Shah to the role of chief commercial officer.Mr Shah has over 20 years’ experience in the pharmaceuticals, biotechnology and healthcare industries.He will spearhead Algorae’s commercial strategy to accelerate growth and expansion into complementary pharmaceutical market segments.Mr Shah was previously employed by Australasian pharmaceutical wholesaler and distributor HPS Pharmacies, where he was instrumental in accelerating the business’s expansion into new markets, forging high-value partnerships and responsible for shaping the company’s procurement strategy and driving revenue growth.Mr Shah has also held senior leadership roles at medical technology giant Baxter Healthcare, including associate director of pharmaceuticals for Asia-Pacific and head of pharmaceuticals for Australia–New Zealand.He helped lead commercial strategy for the $27 billion firm, executi","market":"nz","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/04/Algorae-Pharmaceuticals-ASX-1AI-Vishal-Shah-appointment.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/04/Algorae-Pharmaceuticals-ASX-1AI-Vishal-Shah-appointment.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-strengthens-leadership-chief-commercial-officer/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2507577995","title":"Algorae Pharmaceuticals advances R&D pipeline as AI-driven drug trials continue","url":"https://stock-news.laohu8.com/highlight/detail?id=2507577995","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2507577995?lang=en_us&edition=fundamental","pubTime":"2025-01-29 10:33","pubTimestamp":1738117993,"startTime":"0","endTime":"0","summary":"Novel treatment development company Algorae Pharmaceuticals  says it is well placed to advance its innovative therapeutic pipeline and artificial intelligence -driven drug discovery plans.In releasing its quarterly results, the company said it is in a strong financial position with $2.4 million in cash as of 31 December 2024, providing sufficient funding for its planned activities.Priorities will include the continued evaluation of drug targets generated by the company’s proprietary AI platform AlgoraeOS and the progression of clinical trial planning.A major focus will be the initiation of in vivo studies for Algorae’s AI-168 treatment for cardiovascular disease.Among the company’s recent highlights was the demonstration of AI-168’s strong cardioprotective effects in preclinical studies conducted at the Victorian Heart Institute at Monash University.In studies comparing AI-168 against FDA-approved beta-blockers across multiple cardiovascular disease models, AI-168 was found to restore ","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Algorae-Pharmaceuticals-ASX-1AI-December-2024-quarterly-results.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2025/01/Algorae-Pharmaceuticals-ASX-1AI-December-2024-quarterly-results.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-research-development-ai-driven-drug-trials/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2487612135","title":"Weekly wrap: record highs followed by a slight slip","url":"https://stock-news.laohu8.com/highlight/detail?id=2487612135","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487612135?lang=en_us&edition=fundamental","pubTime":"2024-11-30 00:30","pubTimestamp":1732897809,"startTime":"0","endTime":"0","summary":"The Australian share market had another positive week, reaching fresh record highs twice before slipping back a little in Friday trade.By the close on Friday the ASX 200 Index was down 0.1% or 8.1 points to 8436.2, as seven of the 11 sectors fell.That followed on from Thursday’s fresh record high of 8444.3 points and meant the index still closed 0.5% higher for the week.Two of the big heroes of Thursday’s rally – heavyweights Commonwealth Bank  and blood products group CSL  set the scene by shedding some of their gains, with CSL’s 1% fall to $282.22 the most severe.Property companies were among the hardest hit by the slide, down 0.7% overall with Scentre’s  1.1% fall to $3.68 and Goodman Group’s  0.8% fall to $37.91 some of the more notable.The influential banking sector also fell, making it difficult for the ASX 200 to produce a positive result.One individual share that reacted to news was almond producer Select Harvests , with shares falling 5.4% to $3.69.","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Record-highs-slight-slip-ASX-Nov-2024.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Record-highs-slight-slip-ASX-Nov-2024.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/weekly-wrap-record-highs-followed-by-slight-slip/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7155","BK7162","CKF.AU","BK7510","BK7005","BK7099","BP8.AU","XJO.AU","BK7508","SGR.AU","BK7511","BK7067","BK7095","1AI.AU","XKO.AU","BK7070","BK7078","CBA.AU","PHO.AU","XAO.AU","BK7028","BK7117","CSL.AU","BK7501","MTS.AU","BK7137","GCM.AU","BK7505","SCG.AU","BK7135","GMG.AU","SHV.AU","WEB.AU","WJL.AU"],"gpt_icon":1},{"id":"2487695372","title":"BUZZ-Australia's Algorae Pharmaceuticals gains after positive drug assessment","url":"https://stock-news.laohu8.com/highlight/detail?id=2487695372","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487695372?lang=en_us&edition=fundamental","pubTime":"2024-11-29 10:27","pubTimestamp":1732847259,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Algorae Pharmaceuticals gains after positive drug assessment** Shares of Algorae Pharmaceuticals 1AI.AX rise as much 14.35 to A$0.008, their highest levels since Nov 21     ** The pha","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241129:nL3N3N005A:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"gpt_icon":0},{"id":"2487710063","title":"Algorae Pharma’s drug AI-168 shows cardioprotection, outperforms beta blockers in pre-clinical studies of proliferation","url":"https://stock-news.laohu8.com/highlight/detail?id=2487710063","media":"Small Caps","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487710063?lang=en_us&edition=fundamental","pubTime":"2024-11-29 09:33","pubTimestamp":1732843980,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals  has announced positive results from pre-clinical studies evaluating the protective qualities of its cardiovascular drug candidate AI-168.The pre-clinical assessments at the Monash Victorian Heart Institute in Melbourne were designed to further evaluate the drug’s formulation and compare its performance with beta blockers using well-established in vitro models of cardiovascular disease.The results demonstrated strong cardioprotective qualities, outperforming existing first-line approved beta blockers in three cardiovascular cell lines used to assess the dysregulation of cell growth caused by common cardiac stressors PDGF and angiotensin II.When treated with AI-168, those cells effectively restored normal cell proliferation after 48 hours.AI-168 will continue to be assessed for medical indications where beta blockers are commonly prescribed—including hypertension, angina, heart failure and arrhythmias, among others.Algorae’s pre-clinical studies on AI-168 have cu","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharma-ASX-1AI-drug-AI-168-cardioprotection-beta-blockers.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharma-ASX-1AI-drug-AI-168-cardioprotection-beta-blockers.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharma-drug-ai-168-cardioprotection-outperforms-beta-blockers-pre-clinical-studies-proliferation/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2487327996","title":"Monash tests show strong cardioprotective qualities for Algorae drug candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=2487327996","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2487327996?lang=en_us&edition=fundamental","pubTime":"2024-11-29 07:43","pubTimestamp":1732837380,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals Ltd  has found that its drug candidate AI-168 has strong cardioprotective qualities, performing better than existing first line FDA-approved beta blockers in three cardiovascular cell lines.These results were based on preclinical studies of AI-168, whose composition was also refined as a result, with Algorae filing an International Patent Cooperation Treaty  application, enabling it to pursue patent protection for the drug candidate in commercially significant jurisdictions.The preclinical tests were undertaken at Monash University Victorian Heart Institute Research Laboratories, and sought to assess the formulation of AI-168 and compare its performance with beta blockers using well-established in vitro models of cardiovascular disease.In terms of intellectual property strategy, Algorae announced the filing of an initial patent application on November 23, with the more recent PCT patent application including data received after that point through the preclinical","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/monash-tests-show-strong-cardioprotective-qualities-for-algorae-drug-candidate-2024-11-29/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7067","PCT","1AI.AU","BK4090"],"gpt_icon":0},{"id":"2486386763","title":"Algorae Pharmaceuticals strengthens advisory board with appointment of Dr Sarah Siggins","url":"https://stock-news.laohu8.com/highlight/detail?id=2486386763","media":"Small Caps","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2486386763?lang=en_us&edition=fundamental","pubTime":"2024-11-28 06:54","pubTimestamp":1732748056,"startTime":"0","endTime":"0","summary":"Algorae Pharmaceuticals  has appointed industry executive Dr Sarah Siggins to its scientific advisory board.Dr Siggins has more than 14 years of pharmaceutical experience, including senior roles at global companies Johnson & Johnson Innovative Medicine  and Bristol-Myers Squibb, where she led the development and execution of medical strategies across neuroscience, oncology, cardiopulmonary and immunology.She holds a doctorate in biosciences from the University of Helsinki and has authored more than 15 peer-reviewed publications.Dr Siggins joins the scientific advisory board following the initial readout this week of 24 artificial intelligence-generated drugs delivered by the AlgoraeOS drug discovery platform.The targets are applicable to a range of oncology medical indications with significant unmet needs including breast and lung cancer, leukaemia and glioblastoma.Algorae chair David Hainsworth said Dr Siggins’ “unparalleled experience” in pharmaceutical innovation and strategic execu","market":"us","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharmaceutical-ASX-1AI-Dr.-Sarah-Siggins-Scientific-Advisory-Board.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharmaceutical-ASX-1AI-Dr.-Sarah-Siggins-Scientific-Advisory-Board.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-advisory-board-appointment-dr-sarah-siggins/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["1AI.AU","BK7067"],"gpt_icon":0},{"id":"2485103040","title":"Algorae Pharmaceuticals to study 24 new drug targets generated by AlgoraeOS AI platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2485103040","media":"Small Caps","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2485103040?lang=en_us&edition=fundamental","pubTime":"2024-11-21 07:56","pubTimestamp":1732147003,"startTime":"0","endTime":"0","summary":"Drug development company Algorae Pharmaceuticals  has finalised an initial catalogue of 24 drug targets generated by Version 1.0 of its Algorae Operating System  platform.The platform was launched in October in collaboration with artificial intelligence  experts at the University of New South Wales.The 24 new drug targets have been reviewed for their commercial and intellectual property potential and will be taken to preclinical studies at an Australian pharmaceutical drug laboratory.The targets are applicable to a range of oncology medical indications with significant unmet needs, including breast and lung cancer, leukaemia and glioblastoma.In vitro preclinical assessments will verify efficacy and safety and serve to de-risk further development within the company or in partnership with other pharmaceutical firms.“This significant expansion highlights the important competitive advantage of AI to predict new therapeutic entities ahead of our competitors relying on conventional approache","market":"hk","thumbnail":"https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharmaceuticals-ASX-1AI-OS-Drug-Discovery-Platform-preclinical-studies.jpg","type":0,"news_type":0,"thumbnails":["https://cdn.shortpixel.ai/client/w_868,q_lossy,to_auto,ret_wait/https://150309019.v2.pressablecdn.com/wp-content/uploads/2024/11/Algorae-Pharmaceuticals-ASX-1AI-OS-Drug-Discovery-Platform-preclinical-studies.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://smallcaps.com.au/algorae-pharmaceuticals-24-drug-targets-generated-os-ai-platform/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"smallcap_stock","symbols":["XJO.AU","BK7067","1AI.AU","XAO.AU","XKO.AU"],"gpt_icon":0},{"id":"2484738669","title":"BRIEF-Algorae Pharmaceuticals Says Cessation Of Co's American Depositary Share Deposit Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2484738669","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484738669?lang=en_us&edition=fundamental","pubTime":"2024-11-18 09:27","pubTimestamp":1731893232,"startTime":"0","endTime":"0","summary":"Nov 18 (Reuters) - Algorae Pharmaceuticals Ltd   :   * CESSATION OF CO'S AMERICAN DEPOSITARY SHARE DEPOSIT AGREEMENT, MARKING END OF TRADING OF ALGORAE SECURITIES ON OTCQB IN USFurther company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["1AI.AU","BK7067"],"gpt_icon":0},{"id":"2484654105","title":"Algorae Pharmaceuticals - Cessation of Co's American Depositary Share Deposit Agreement, Marking End of Trading of Algorae Securities on Otcqb in US","url":"https://stock-news.laohu8.com/highlight/detail?id=2484654105","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2484654105?lang=en_us&edition=fundamental","pubTime":"2024-11-18 06:04","pubTimestamp":1731881059,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241117:nFWN3MO003:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","1AI.AU"],"gpt_icon":0},{"id":"2482876757","title":"ASX Penny Stocks To Watch In November 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482876757","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482876757?lang=en_us&edition=fundamental","pubTime":"2024-11-11 15:05","pubTimestamp":1731308737,"startTime":"0","endTime":"0","summary":"The Australian market has experienced a downturn, with the ASX200 closing down 0.35% at 8266 points, as investors reacted to underwhelming Chinese stimulus measures and subsequent declines in commodity prices. In this context, identifying promising investment opportunities requires careful consideration of market dynamics and sector performance. While the term \"penny stock\" may seem outdated, it still signifies smaller or newer companies that can offer substantial value when backed by strong...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/3242000-choice1-main-header/1585186612362","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/3242000-choice1-main-header/1585186612362"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/transportation/asx-lau/lindsay-australia-shares/news/asx-penny-stocks-to-watch-in-november-2024-2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7048","BK7163","PRN.AU","XAO.AU","BK7062","MXI.AU","BK7095","ANG.AU","NGI.AU","BK7114","BK7125","HLO.AU","ODA.AU","BK7132","SHA.AU","BRI.AU","BK7077","BK7067","BK7070","XKO.AU","LBL.AU","BK7016","EZZ.AU","BK7055","XJO.AU","EVO.AU","BK7088","LAU.AU","1AI.AU"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":14,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/1AI.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"1AI.AU\",market:\"AU\",,,undefined,":[]}}